• Search
  • Helpdesk
  • Sales contact

Tackling the specificities of NASH/MASH clinical trials

Last updated: May 7, 2025

Integrating PROs into studies on MASH, also known as NASH, is crucial. 
MASH is a debilitating chronic illness that significantly impairs patients’ quality of life, affecting their daily routines, work, and mobility.

  • Patient-centric appraisals are needed in the quest for treatments
  • Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients’ concerns


At Kayentis, we have the full capability to run your MASH studies successfully:

  • We have extensive experience in MASH and hepatic disorders research
  • We offer an enhanced patient-centric eCOA data entry
  • We are a key partner to biotech and big pharma companies
 
Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

DPHARM 2026

SEPT 15-16 2026 • Boston, MA, USA
Meet our team Andrea Murison and Jim Tolley at Booth #306 at DPHARM Conference | Home  Schedule a meeting

SCDM 2026

Raleigh, South Carolina, USA - 14-17 SEPT 2026
Meet our team Chris Barden and Chris Kemper at booth #342, at the Annual Conference 2026 – SCDMLive Schedule a meeting

SCOPE Europe 2026

OCT 13-14 2026 • Barcelona, Spain
Meet our team Chris BARDEN and Björn FELBER at SCOPE Europe Schedule a meeting

ISOQOL 2026

18-21 OCT 2026 • Prague, Czech Republic
33rd Annual Conference | ISOQOL